UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.